Sheldon L. Koenig - 29 Oct 2021 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role
President and CEO, Director
Signature
/s/ Richard B. Bartram, by power of attorney
Issuer symbol
ESPR
Transactions as of
29 Oct 2021
Net transactions value
$0
Form type
4
Filing time
01 Nov 2021, 16:48:58 UTC
Previous filing
18 May 2021
Next filing
16 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ESPR Common Stock Award $0 +26,700 +53% $0.000000 76,700 29 Oct 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ESPR Stock Option (right to buy) 37,850 29 Oct 2021 Common Stock 37,850 $8.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The awards will vest as follows: 50% shall vest upon CVOT public presentation of results; and 50% shall vest upon obtaining approval for cardiovascular risk reduction into the U.S. label.